Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Revive Therapeutics Ltd
(OP:
RVVTF
)
0.0128
-0.0012 (-8.57%)
Delayed Quote
Updated: 3:31 PM EST, Nov 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Revive Therapeutics Ltd
< Previous
1
2
3
Next >
Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases
September 15, 2026
Company aims to build a globally protected bucillamine franchise spanning medical countermeasures, orphan diseases and government preparedness programs
From
Revive Therapeutics Ltd.
Via
ACCESS Newswire
Revive Therapeutics Announces Proposed Shares for Debt Settlement
August 19, 2026
From
Revive Therapeutics Ltd.
Via
ACCESS Newswire
Revive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics Portfolio
August 19, 2026
From
Revive Therapeutics Ltd.
Via
ACCESS Newswire
Revive Therapeutics Reports Grant of Options
August 14, 2026
From
Revive Therapeutics Ltd.
Via
ACCESS Newswire
Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures
May 20, 2026
Via
ACCESS Newswire
Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases
March 11, 2026
Via
ACCESS Newswire
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
December 15, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
November 21, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Closing of Second Tranche of Private Placement
September 19, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Extension of Proposed Private Placement
September 05, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement
August 11, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Proposed Private Placement and Debt Settlement
July 30, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study
July 08, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity
June 26, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Advances with Next-Generation Bucillamine Development
June 04, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
May 12, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Proposed Shares for Debt Transaction
April 21, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment
April 10, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program
April 01, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Results of Annual Shareholder Meeting
March 19, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
DiagnaMed Granted FDA Orphan Drug Designation for Molecular Hydrogen to Treat Amyotrophic Lateral Sclerosis
March 03, 2025
Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) ("DiagnaMed", "DMED", or the "Company"), a leading...
Via
Newsfile
Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program
March 03, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
February 03, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
January 08, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke
November 12, 2024
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
October 31, 2024
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
September 18, 2024
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections
August 28, 2024
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
July 02, 2024
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID
June 12, 2024
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
